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Abstract
The atypical antipsychotic clozapine is the only effective medication for treatment-resistant schizophrenia. However, it
can also induce serious adverse drug reactions, including agranulocytosis and neutropenia. The mechanism by which
it does so is largely unknown, but there is evidence for contributing genetic factors. Several studies identified HLA-
DQB1 variants and especially a polymorphism located in HLA-DQB1 (6672G>C, rs113332494) as associated with
clozapine-induced agranulocytosis and neutropenia. We analysed the risk allele distribution of SNP rs113332494 in a
sample of 1396 controls and 178 neutropenia cases of which 60 developed agranulocytosis. Absolute neutrophil
counts of 500/mm3 and 1500/mm3 were used for defining agranulocytosis and neutropenia cases, respectively. We
also performed association analyses and analysed local ancestry patterns in individuals of European ancestry, seeking
replication and extension of earlier findings. HLA-DQB1 (6672G>C, rs113332494) was associated with neutropenia (OR
= 6.20, P= 2.20E−06) and agranulocytosis (OR= 10.49, P= 1.83E−06) in individuals of European ancestry. The
association signal strengthened after including local ancestry estimates (neutropenia: OR= 10.38, P= 6.05E−08;
agranulocytosis: OR= 16.31, P= 1.39E−06), with effect sizes being considerably larger for agranulocytosis. Using local
ancestry estimates for prediction, the sensitivity of rs113332494 increased from 11.28 to 55.64% for neutropenia and
from 16.67 to 53.70% for agranulocytosis. Our study further strengthens the evidence implicating HLA-DQB1 in
agranulocytosis and neutropenia, suggesting components of the immune system as contributing to this serious
adverse drug reaction. Using local ancestry estimates might help in identifying risk variants and improve prediction of
haematological adverse effects.
Introduction
Clozapine is the most effective antipsychotic medica-
tion, particularly for treatment resistant patients where
clozapine is the only evidence based option1–3. Compared
to alternative antipsychotics it offers superior symptom
control, longer duration of treatment, reduced hospitali-
sation, improved cognition, better work and social func-
tion, a higher quality of life and reductions in violence and
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in suicidality4,5. However, due to serious adverse drug
reactions, including agranulocytosis, clozapine treatment
is only indicated in patients who have failed at least two
other antipsychotics. To minimize the risk of agranulo-
cytosis, frequent blood monitoring is required which
represents another restriction to its use in an often chal-
lenging population of patients6.
The ability of clozapine to induce abnormally low
concentration of neutrophils, which can predispose
patients to serious and potentially lethal infections, has
been recognised for several decades. Neutropenia and
agranulocytosis describe absolute neutrophil counts
(ANCs) below 1500 and 500 cells/mm3, respectively. In
1975, treatment of 2260 patients with clozapine was
associated with agranulocytosis in 16 patients, 8 of whom
died7, leading to clozapine withdrawal from the market in
many countries. Clozapine was still prescribed in German
speaking countries and Finland and reintroduced in other
countries in 1990 under strict conditions which required
regular blood count monitoring8. The incidence of neu-
tropenia and agranulocytosis has recently been reported
as 3.8% (95% CI: 2.7–5.2%) and 0.9% (95% CI: 0.7–1.1%),
respectively9.
The mechanisms underlying clozapine-induced hae-
matological adverse effects are largely unknown. There is
evidence for toxic, immunological and genetic mechan-
isms indicating a multi-factorial pathogenesis. Agranulo-
cytosis seems to be an idiosyncratic reaction, is dose-
independent and is influenced by genetic or environ-
mental factors10. Whereas neutropenia has been proposed
to be a direct toxic effect of the parent drug, agranulo-
cytosis seems to be the result of a toxic event involving an
unstable intermediate metabolite, a nitrenium ion10,11.
Binding of this ion to neutrophil proteins could lead to
either a disturbance of neutrophil function or hapten
formation, thereby triggering the immune destruction of
the neutrophil11. The possibility of an underlying immu-
nological mechanism is indicated by findings that a more
severe and rapid course of agranulocytosis can occur after
re-exposure to clozapine as well as studies identifying risk
variants located in the major histocompatibility complex
(MHC)12,13. Benign ethnic neutropenia (BEN) is char-
acterized by low neutrophil counts not associated with an
increased risk of infections and shows an increased pre-
valence in individuals of African or Middle Eastern
ancestry, potentially due to the contribution of genetic
variants that are rare elsewhere14,15. These ancestry
dependent differences, and the fact that other adverse
drug reactions also have genetic mediators, present a
strong argument that genetic factors explain, at
least partly, inter-individual variability and differences
in bioactivation, detoxification and immunological
response11,16,17.
Very few genetic markers have been clearly associated
with clozapine induced agranulocytosis or neutropenia.
Identified genetic risk factors include specific human
leucocyte antigen (HLA) variants and haplotypes12,18. The
HLA region was first implicated in small studies that
identified the HLA allele DQB1*05:02 as risk factor for
agranulocytosis in patients of European ancestry19,20.
Evidence strengthened when Athanasiou et al. analysed 74
candidate genes in a cohort recruited from sites within the
USA, Russia and South Africa in order to replicate the
findings in a second cohort of non-Jewish schizophrenia
patients of German descent21. Only variants in HLA-
DQB1 were significantly associated with agranulocytosis
in both cohorts. A subsequent refinement analysis
revealed association to a single SNP (HLA-DQB1
6672G>C, rs113332494, OR= 16.9), which is in strong
linkage disequilibrium (LD) with DQB1*05:0222. Although
two other smaller studies were not able to replicate these
findings23,24, substantial evidence for the importance of
the HLA-DQB1 region has also come from the largest
genome-wide association studies (GWAS) conducted to
date22,25. The Clozapine-Induced Agranulocytosis Con-
sortium (CIAC) analysed imputed HLA alleles and amino
acid changes in 162 patients and 4319 controls. Clozapine
treated cases (ANC ≤ 1000) were compared to two
populations: patients with schizophrenia treated with
clozapine for at least 1 year without developing neu-
tropenia (ANC > 1500) and population controls. Two
genome-wide associated variants were identified, includ-
ing a single non-synonymous variant in HLA-DQB1
(126Q) (OR= 0.19, P= 4.7E−14), for which the most
common HLA allele at high-risk is HLA-DQB1*05:0222.
Moreover, rs113332494 was genotyped in a British sample
of 60 clozapine-treated cases and 305 clozapine-treated
controls and again, significantly associated with
neutropenia (OR= 15.6, P= 0.015). The association
strengthened (OR= 38.1, P= 0.0079) using a stricter
ANC threshold of 1000mm−3 25.
The variant rs113332494 is located in the MHC region
on chromosome 6, a region with extensive LD spanning
more than 3Mb. The region is highly polymorphic and
this variability is maintained by positive natural selec-
tion26. Population-specific recombination sites might
contribute to the high diversity of haplotypes27 and it has
been shown that the region exhibits an excess of local
ancestry switches in non-European populations26,28. A
local ancestry switch is defined as a genomic region
exhibiting a change in ancestry, such that while most
haplotypes across the broader region originate from one
ancestral population, local haplotypes in a subregion
might be derived from a different population as a result of
recombination. Interestingly, an increase in East Asian
ancestry haplotypes in the HLA-DQB1 region was found
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in a neutropenia case–control sample of British ances-
try25. The switch was seen in cases and controls, but
nevertheless, local ancestry switches could be additional
relevant factors influencing disease risk.
In order to replicate and refine previous findings and
clarify the influence of the marker on the risk of neu-
tropenia and agranulocytosis, we analysed the risk allele
distribution, global and local population structure and
association of the marker rs113332494 with neutropenia
and agranulocytosis in 1396 controls and 178 neutropenia
cases of which 60 developed agranulocytosis. To the best
of our knowledge, this is the first study which determines




The CRESTAR sample comprised 1576 clozapine treated
individuals, 1396 controls and 180 neutropenia cases of
which 61 developed agranulocytosis (Supplementary Tables
S1 and S2). Any psychiatric diagnosis was allowed; the
primary psychiatric diagnosis was schizophrenia. ANC
thresholds of 500/mm3 or 1500/mm3 were used for defining
agranulocytosis and neutropenia cases, respectively. A small
number of cases (N= 22, 3 agranulocytosis and 19 neu-
tropenia cases) were classified by clinical judgement due to
a precipitous drop in ANC while being intensively mon-
itored. A detailed description of all contributing groups and
inclusion criteria can be found in Supplementary Material.
Overlap to other studies
Overlaps to CIAC22 and CLOZUK25 were examined by
identity-by-descent estimations. Using genome-wide data
we identified a small number of individuals (eight con-
trols, seven cases) of European ancestry as duplicates in
CIAC. These individuals were not excluded, as the mar-
ker, which is the focus of the present study, was not
imputed at adequate quality in the GWAS conducted by
that consortium. Overlap to CLOZUK cases was checked
by identifying duplicates and first-degree relatives using
~1000 markers. One neutropenia and one agranulocytosis
case were excluded from association and prediction ana-
lyses as they were found to be part of the CLOZUK study.
See Supplementary Material for details and a sensitivity
analysis excluding the individuals overlapping with CIAC.
Genotyping/Imputation
Individuals were genotyped on Illumina
HumanOmniExpress-12v1 and standard quality checks
were applied (see Supplementary Methods). Pre-phasing
was performed with SHAPEIT229 and imputation with
IMPUTE230,31. We used the reference panel 1000 Gen-
omes Project Phase 1 (August 2012), provided by the
SHAPEIT2 authors, for both steps.
Population structure
Population structure was analyzed by EIGENSTRAT
(Supplementary Fig. S1) and an admixture analysis in a
supervised setting using African (AFR), East Asian (EAS)
and European (EUR) 1000 Genomes Project (1 KG) super
populations as reference using ADMIXTURE v1.3.032.
African (N= 48) and European (N= 1006) subsamples
were defined as individuals with at least 80% AFR or EUR
ancestry fractions. All other individuals were defined as
admixed (N= 522).
Statistical analysis
The statistical analysis included 1574 individuals (1396
controls, 178 neutropenia cases of whom 60 developed
agranulocytosis) once the two duplicate individuals from
CLOZUK were excluded (see above).
Risk allele distribution of marker rs113332494 was
examined based on best guess genotypes derived from
PLINK v1.933,34 using the following parameters: --hard-
call-threshold 0.3, --geno 0.1, --maf 0.01, --hwe 1E-05.
Genotypes with posterior probabilities below 0.7 were set
to missing.
Association analysis was performed on individuals of
European ancestry using logistic regression in PLINK
v1.933,34 applying an additive model corrected for relevant
principal components inferred by EIGENSTRAT v6.0.135.
Supplementary Fig. S2 shows the scatterplot of first two
principal components.
The main association analyses were conducted on
neutropenia (ANC ≤ 1500) and agranulocytosis (ANC ≤
500). To investigate the contribution of agranulocytosis
cases, we excluded all cases with ANC ≥ 500 and tested a
range of ANC thresholds (500–1500 in steps of 100). We
also analysed different ANC thresholds excluding neu-
tropenia cases for a range of ANC thresholds in steps of
100 to determine how rs113332494 behaves as a
predictor.
Estimating local ancestry haplotypes across the exten-
ded MHC region (25–35Mb) was performed with ELAI36
using the 1KG super populations EUR, EAS and AFR as
reference. We set the number of upper clusters, lower
clusters and mixture generations to 3, 15 and 200 as
recommended by the software author. Inference was
performed with 20 EM steps and averaged over ten
replicates. The contribution of each of the three ancestral
populations is given as an allele dosage estimate ranging
from 0 to 2, corresponding respectively to no or complete
contribution of the reference haplotype. Means for the
region of interest were averaged across 1 kb up- and
downstream from rs113332494. Mean dosage estimates of
a single ancestral population and normed differences
of two populations [POP1/(POP1+ POP2)− POP2/
(POP1+ POP2)] were compared between groups. Per-
mutation tests were used to derive the significance of
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group comparisons. We conducted 10,000 permutations
shuffling group membership while keeping the group size
constant.
Best guess genotypes with maximum posterior prob-
ability > 0.7 were used to determine the predictive power
of rs113332494. The risks in the high- and low-risk group
as well as positive and negative predictive value were
calculated with respect to the assumed risk of agranulo-
cytosis (0.9%) and neutropenia (3.8%)9. Individuals were
classified as “high risk” when carrying the risk allele G,
additionally local ancestry information was used in a
second model.
Power calculations were performed with Quanto37
using a log-additive model. Power was derived using the
estimated allele frequencies and case–control ratios set-
ting the prevalence for neutropenia and agranulocytosis to
3.8 and 0.9%9.
SNP annotations, conservation scores and LD plots
were derived with SNiPA38. For annotation of marker
effects see https://snipa.helmholtz-muenchen.de/snipa3/




We examined rs113332494 risk allele (G) carriers and
the distribution of risk alleles in individuals of different
ancestries (N= 1574). The study sample was mainly
comprised of individuals of European (N= 1004, 133
cases) ancestry, but also included individuals of African
(N= 48, 15 cases) and admixed (N= 522, 30 cases)
ancestry. Eight controls had maximum genotype posterior
probabilities below the threshold (0.7) and were set to
missing. We found 68 (4.3%) risk allele carriers in the
1566 remaining individuals, 52 (3.7% of 1396) controls
and 16 (9.0% of 178) cases of which 9 (15.0% of 60)
developed agranulocytosis. Fourteen cases were con-
firmed by neutrophil counts, whereas two cases (one
neutropenia, one agranulocytosis) were confirmed by
clinical judgement (blind to genotype). Of the 68 risk
allele carriers, 66 had a diagnosis of schizophrenia, the
other 2 had diagnoses of bipolar affective disorder and
psychosis. We found 45 (15 cases) risk allele carriers of
European, 6 (1 case) of African and 17 (0 cases) of mixed
ancestry (Supplementary Fig. S3, Supplementary Table
S3). The risk allele frequency for all 1566 individuals was
2.2%, which is in line with all non-Asian 1KG phase 1
populations (2.4%). Finnish (1.8%) and EUR (2.3%) fre-
quencies also agree with the estimates of the reference
populations (FIN= 1.6%, EUR= 2.5%). The risk allele in
the European sample was three times more frequent in
cases than in controls. In contrast, the risk allele was more
common in African ancestry controls compared with
cases. We found no admixed ancestry cases carrying the
risk allele. All subsequent analyses were conducted in
individuals of European ancestry only.
Local ancestry of the HLA-DQB1 region
We estimated local ancestry patterns in the extended
MHC region and investigated the contribution of African,
East Asian and European haplotypes in the region sur-
rounding rs113332494 in individuals of European ances-
try (N= 1004). In general, European dosage estimates
dominated, but decreased in the HLA-DQB1 region. Cases
had higher African and lower East Asian local ancestry
estimates than controls (Supplementary Fig. S4). Addi-
tional stratification by rs113332494 revealed two striking
patterns. First, risk allele carriers exhibited considerably





















Population AFR EAS EUR
Fig. 1 Local ancestry dosage estimates. Local ancestry dosage
estimates of risk allele (A) and non-risk allele carriers (B) were
estimated by ELAI using 1KG AFR, EAS and EUR super populations as
reference (green= AFR, blue= EAS, red= EUR). Means for the region
of interest were averaged across 1 kb up and downstream from
rs113332494. Risk allele status was defined using best guess
genotypes with posterior probability > 0.7.
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EUR= 0.44) (Fig. 1A, Supplementary Fig. S5A, C, E),
whereas in non-carriers EUR local haplotypes dominated
(EAS= 0.64, EUR= 0.89) (Fig. 1B, Supplementary Fig.
S5B, D, F). Second, in the group of non-risk allele carriers,
cases exhibited higher African and lower East Asian
dosage estimates compared to controls (AFR controls=
0.45, AFR neutropenia= 0.60; EAS controls= 0.67, EAS
neutropenia= 0.45) (Fig. 1B, Supplementary Fig. S5B, D,
F). Patterns were similar for neutropenia and agranulo-
cytosis cases.
The significance of group differences assessed by per-
mutation testing is presented in Table 1. Risk allele car-
riers had significantly higher East Asian ancestry estimates
than non-risk allele carriers (P < 1.00E−04). In addition,
we found significant differences of East Asian (P < 1.00E
−04) and African (P= 1.20E−03) ancestry in non-risk
allele carriers between neutropenia cases and controls.
The difference of AFR and EAS estimates also differed
significantly between neutropenia cases and controls
regardless of risk allele status, but this effect was driven by
the difference in non-risk allele carriers, as there was no
significant difference in risk allele carriers. Results were
similar when restricting to agranulocytosis cases (Sup-
plementary Tables S4 and S5).
Association analyses
We performed an association analysis of the marker
HLA-DQB1 6672G>C (rs113332494) in a European
sample comprised of 871 controls, 133 neutropenia and
54 agranulocytosis cases. The risk allele was more fre-
quent in cases (neutropenia= 5.4%, agranulocytosis=
8.0%, controls= 1.8%) and the variant was significantly
associated with neutropenia (OR= 6.20, 95% CI:
2.91–13.21, P= 2.20E−06) and agranulocytosis (OR=
10.49, 95% CI: 3.99–27.56, P= 1.83E−06) (Table 2).
Including AFR and EAS dosage estimates as additional
covariates in association analyses gave higher odds ratio
estimates (neutropenia: OR= 10.38, 95% CI: 4.45–24.22,
P= 6.05E−08; agranulocytosis: OR= 16.31, 95% CI:
5.25–50.68, P= 1.39E−06), with the P value in the neu-
tropenia analysis almost reaching genome-wide sig-
nificance (Table 2). We had 100% power to detect effects
in the size of the estimated odds ratios given the estimated
allele frequency and case–control ratio. A sensitivity
analysis including age and gender as covariates revealed
associations and odds ratios of comparable strength and
effect size (Supplementary Table S6).
Linear effect of ANC
The odds ratio estimates were higher for agranulocy-
tosis than for neutropenia. To determine if the effect on
neutropenia is driven by inclusion of those with agranu-
locytosis, we excluded all cases with ANC ≥ 500 and tes-
ted a range of ANC thresholds (500–1500 in steps of 100)
(Supplementary Table S7). The association diminished
when excluding all agranulocytosis cases but was still
significant, odds ratios decreased slightly with higher
ANC thresholds (Supplementary Table S7, Supplemen-
tary Fig. S6). To determine how rs113332494 behaves as a
predictor we also analysed different ANC thresholds
excluding neutropenia cases for a range of ANC thresh-
olds in steps of 100 (Supplementary Table S8). The odds
ratios nearly followed a linear trend, where estimates
decreased with higher ANC thresholds (Fig. 2).
Predictive test characteristics
Predictive power was established by comparing affec-
tion to risk allele status, where heterozygote and homo-
zygote risk allele carriers were combined. The HLA-DQB1
variant had high specificity, but low sensitivity in pre-
dicting risk for agranulocytosis and neutropenia (Table 3).
Sensitivity was higher in agranulocytosis (17%) cases in
comparison to those with neutropenia (11%). Classifying
all individuals carrying the rs113332494 risk allele as “high
Table 1 Local ancestry estimates in individuals of European ancestry for ancestral populations AFR, EAS and EUR.
Ancestral population Non-risk vs risk allele carriers Non-risk allele carriers: controls vs cases
Dosage Difference P value dosage difference P value
AFR 0.470/0.213 0.257 <1.00E−04 0.452/0.600 −0.148 1.20E−03
EAS 0.641/1.344 −0.703 <1.00E−04 0.668/0.452 0.216 <1.00E−04
EUR 0.889/0.443 0.446 <1.00E−04 0.881/0.948 −0.067 8.31E−02
AFR–EAS −0.154/−0.726 0.573 <1.00E−04 −0.193/0.141 −0.334 <1.00E−04
AFR–EUR −0.308/−0.351 0.043 3.40E−01 −0.322/−0.224 −0.098 5.77E−02
EAS–EUR −0.162/0.504 −0.666 <1.00E−04 −0.138/−0.353 0.216 9.00E−04
Dosage means for single ancestral populations and normed differences for two populations were compared between risk (N= 45) and non-risk allele (N= 956)
carriers as well as between controls (N= 838) and neutropenia cases (N= 118) not carrying the risk allele. P values were determined by permutation tests (N=
10,000). Significant results are in bold.
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risk” and classifying non-risk allele carriers with respect to
the difference in African and East Asian ancestry esti-
mates (positive: higher AFR= “high risk”, negative: lower
AFR= “low risk”) resulted in a substantial increase in
sensitivity (neutropenia= 56%, agranulocytosis= 54%),
but also a decrease in specificity (Table 3).
Discussion
Our study shows an association between rs113332494
(HLA-DQB1 6672G>C) and clozapine-induced neu-
tropenia and agranulocytosis, further adding to the evi-
dence of the importance of this genetic variant. The
estimated odds ratio for agranulocytosis was higher (OR
= 10.49, P= 1.83E−06) than for neutropenia (OR= 6.20,
P= 2.20E−06). Exclusion of individuals with agranulo-
cytosis revealed a residual, but diminished association
signal, in those with neutropenia. Additional association
analyses including cases with varying ANC thresholds
(500–1500) showed that effect sizes increased linearly
with stricter ANC thresholds. Most likely, this indicates
that neutropenia cases are composed of two different
populations: (1) individuals who would have developed
agranulocytosis if clozapine had not been stopped and (2)
individuals who show decreased ANC because of random
fluctuation or other factors not related to clozapine-
induced agranulocytosis. In this scenario, it might be the
case that the number of “true” agranulocytosis cases
increases as ANC counts decline.
Given the complex recombination pattern of the MHC
region, it is unclear if rs113332494, which is intronic, is
itself the causal variant rather than simply indicating an
indirect association with another variant with which
it is in LD. Annotations revealed three SNPs in
strong LD (r2 > 0.8) to rs113332494 in the European
population: rs41542812 (r2= 0.95, direct transcript
effect), rs113664950 (r2= 0.89, putative regulatory/tran-
script effect) and rs114262759 (r2= 0.84, putative tran-
script effect). The missense variant rs41542812 is a
glutamine to histidine polymorphism at position 158.
Rs113664950 is annotated as expressed promoter (FAN-
TOM5) for DQB1 and promoter-associated distal DHS
(enhancer) for PBX2, TAP1, HLA-DRB9, HLA-DQA1,
HLA-DPA1, HLA-DQB1, HLA-DQA1, PBX2, HLA-DRB5,
HLA-DOA and HLA-DPA1 (ENCODE). Interestingly, this
variant is also associated with bare lymphocyte syndrome
type I. Given the high LD between the investigated variant
and rs113664950, an association of rs113332494 with this
syndrome seems possible. One of twenty one variants in
middle to high LD (0.6 < r2 < 0.8) showed a direct reg-
ulatory effect: rs35139945 (r2 > 0.74), which is a cis-eQTL
variant for HLA-DQA1, HLA-DRB5 and HLA-DRB1.
Among other tissues differentially regulated, gene
Table 2 Results of association analyses of rs113332494 for neutropenia and agranulocytosis including 1004 and 925
individuals of European ancestry.
Phenotype N cases N controls Info Freq cases Freq controls Global ancestry Global and local
ancestry
OR 95% CI P value OR 95% CI P value
Neutropenia 133 871 0.962 0.054 0.018 6.20 2.20E−06 10.38 6.05E−08
2.91–13.21 4.45–24.22
Agranulocytosis 54 871 0.969 0.080 0.018 10.49 1.83E−06 16.31 1.39E−06
3.99–27.56 5.25–50.68
Estimates are given for risk allele G. Global ancestry: association results corrected for principal components (PC1–PC7). Global and local ancestry: association results
corrected for principal components (PC1–PC7) and local ancestry estimates for ancestral populations AFR and EAS. Significant results are in bold.
Freq frequency of risk allele G, OR odds ratio for risk allele G, 95% CI 95% confidence interval for odds ratio.











Global and local ancestry
Fig. 2 Odds ratio estimates for varying ANC thresholds
(500–1500). Odds ratios were determined in association analyses of
European individuals corrected for global (principal components
PC1–PC7) and additionally for local ancestry (dosage estimates for
ancestral populations AFR and EAS). Regression lines were determined
by weighted least squares regression where the reciprocals of the
standard errors were used as weights.
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expression has been shown in blood39. LD decreases in
the downstream direction of HLA-DQB1 overlapping
HLA-DQA1 (r2 > 0.7) and the HLA-DRB1-DRB6 (pseudo)-
DRB5 region (r2 > 0.4) in the European population (Fig. 3),
whereas in African and Asian populations, the regions
including high to low LD variants are more sharply lim-
ited surrounding the region of interest (Supplementary
Fig. S7). Which variant(s) in this region is/are causal and
whether variations in this region contribute to the risk in
specific populations only remain subject to further
investigation.
There is evidence that besides global population patterns,
local haplotypes might be a relevant feature in the HLA-
DQB1 region. An excess of ancestry switches was reported
Table 3 Predictive test characteristics of rs113332494 including 868 controls and 133 neutropenia cases (ANC ≤ 1500) of
which 54 developed agranulocytosis (ANC ≤ 500).
Phenotype Neutropenia Neutropenia Agranulocytosis Agranulocytosis
Risk Predictor rs113332494 rs113332494+ LAE rs113332494 rs113332494+ LAE
True positives 15 74 9 29
False positives 30 336 30 336
False negatives 118 59 45 25
True negatives 838 532 838 532
Sensitivity 0.1128 0.5564 0.1667 0.5370
Specificity 0.9654 0.6129 0.9654 0.6129
Risk in high-risk group 0.1142 0.0537 0.0420 0.0124
Risk in low-risk group 0.0350 0.0278 0.0078 0.0068
PPV 0.1142 0.0537 0.0420 0.0124
NPV 0.9650 0.9722 0.9922 0.9932
RR 0.3328 0.7073 0.2145 0.7233
Risk predictor= rs113332494: Individuals were classified as “high risk” when carrying the risk allele G. Genotype counts are based on best guess genotypes with
maximum posterior probability > 0.7. Risk predictor= rs113332494+ local ancestry estimates: Individuals were classified as “high risk” when carrying the risk allele G.
In addition, non-risk allele carriers were classified as “high risk” when they exhibited larger AFR dosage estimate compared to EAS. Risk of neutropenia and
agranulocytosis were set to 0.009 and 0.038. The risks in the high- and low-risk group as well as positive and negative predictive value were calculated with respect to
the assumed risk of agranulocytosis and neutropenia. The relative risk corresponds to the proportion of the assumed risk vs. the risk in the high-risk group.
LAE local ancestry estimate, PPV positive predictive value, NPV negative predictive value, RR relative risk.
Fig. 3 Linkage disequilibrium plot. Linkage disequilibrium of rs113332494 with surrounding markers coloured by strength of LD in 1 KG European
super population.
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for several populations and European ancestry was shown
to diminish across the HLA-DQB1 region in a British study
on neutropenia. We determined the local haplotype struc-
ture in a sample without overlapping cases and also found
decreasing European contribution to the region surround-
ing the marker rs113332494. The analysis revealed a sub-
stantial increase of East Asian local haplotypes in risk allele
carriers, whereas in non-risk allele carriers European allele
dosage estimates dominated. This pattern was present in
cases and controls and thus did not provide additional
information for risk detection or prediction. Interestingly,
we also found significantly lower EAS and higher AFR
dosage estimates in cases compared to controls not carrying
the risk allele. Furthermore, including the local haplotype
information substantially strengthened the association with
both neutropenia (OR= 10.38, P= 6.05E−08) and agra-
nulocytosis (OR= 16.31, P= 1.39E−06). However, local
ancestry inferences should not be interpreted as conclusive
assignments of haplotypes to specific populations40, as the
resolution of the reference panel might not be enough to
resolve the observed pattern of genetic diversity. In addi-
tion, it is not clear how the input sample or the choice of
markers influences local ancestry estimates and if the effect
is additive as was assumed in this study. Nevertheless, if
further evaluated and replicated, these results could con-
tribute to improve prediction of haematological side effects.
Individuals of African ancestry have a higher prevalence
of BEN14. This study included individuals with >80%
global European ancestry patterns. Thus, one might
speculate that higher local African ancestry in those with
low ANC might be related to global African ancestry
patterns, and specifically, a higher propensity for BEN.
However, local and global African ancestry do not cor-
relate in non-risk allele carriers (controls: Kendall’s tau-b
= 0.003, P= 0.89, neutropenia: Kendall’s tau-b= 0.024, P
= 0.74), suggesting that the local effect is not driven by
uncontrolled effects of global ancestry. Moreover, among
all non-risk allele carriers, we found only one individual,
who was actually a control, who was homozygous for the
C-allele at SNP rs2814778, which is actually thought to be
the causal genotype for BEN, and is a better predictor of
BEN than global ancestry15. Thus, our finding appears to
reflect local, not genome-wide, effects of African ancestry
beyond those indexed by rs113332494. The observation of
a local effect of African ancestry independent of
rs113332494 suggests that there are either additional
causal alleles within the region that are enriched in people
of African ancestry, and/or that rs113332494 is not causal
but is instead in LD with the causal variant.
To be of clinical use, a predictive pharmacogenetic test
should be sufficient to identify individuals for which the
risk of developing adverse effects is low enough to make
blood monitoring either unnecessary or reduce the fre-
quency by which it is performed. This corresponds to a
low risk of developing adverse effects in the group of non-
risk allele carriers. Verbelen et al. analysed the char-
acteristics of a useful predictive variant and showed that
the key factor is high sensitivity, especially in combination
with a low frequency of risk allele carriers. Sensitivity or
the true positive rate for a test denotes the proportion of
individuals developing a side effect who are positive for
the test, high sensitivity implying that the number of
people falsely classified as being not at risk is low. In the
context of high sensitivity, a low-risk allele frequency also
implies that the absolute numbers of people correctly
classified as being not at risk is larger, and thus blood
monitoring can be relaxed for a large number of indivi-
duals. Assuming an acceptable risk of 0.13% (corre-
sponding to the risk of chlorpromazine which does not
require extensive blood monitoring in the UK) for agra-
nulocytosis in the group of non-risk allele carriers and an
agranulocytosis risk of 0.9%, sensitivity must be at least
85.7%41 in order to relax monitoring in those that are not
positive for the test (i.e. do not have the high-risk allele).
As in earlier studies, where sensitivity was found to be
21.521 and 5%25, we failed to reach the required threshold.
However, using local ancestry estimates for prediction,
the sensitivity of rs113332494 increased from 11.28 to
55.64% for neutropenia and from 16.67 to 53.70% for
agranulocytosis, thus coming closer to the goal of using
variants as a predictive tool to give patients the chance of
getting an effective treatment as soon as possible and with
minimal disruption.
While our results show the importance of the marker
under study, they should be viewed in light of some
limitations. First of all, the sample size is arguably small,
but this is unavoidable given the low prevalence of agra-
nulocytosis. For this reason, the project allowed the
inclusion of patients of all ancestries. However, the ana-
lysis of the risk allele distribution showed that we do not
have enough samples to conduct an association analysis in
individuals of African, Asian or mixed ancestry and thus is
limited to individuals of European ancestry. Second, the
current study is limited to one single SNP. The variant
was not imputed with enough quality in other GWAs, but
has been replicated in independent samples and is thus of
special interest. Therefore, we conducted additional ana-
lyses for refinement of findings, while genome-wide ana-
lyses are underway. Third, different groups recruited
patients under different conditions. While following
standardized guidelines, some patients were recruited in
hospitals during treatment, others were recruited from
registers where the available information on clinical and
demographic features was limited (see Supplementary
Information). For example, treatment compliance was
monitored and good compliance was defined as clinical
impression > 80% of dosage and/or consistently docu-
mented plasma levels. However, plasma levels could not
Konte et al. Translational Psychiatry          (2021) 11:214 Page 8 of 10
be included in the statistical analysis, as this information
was not available for all study subjects. Last, the neu-
tropenia sample might also include individuals who would
have developed agranulocytosis if clozapine had not been
stopped, but this follows the monitoring guidelines in
countries of contributing groups and is the situation
encountered in clinical practice.
In summary, we were able to replicate previous findings
for an association of rs113332494 (HLA-DQB1 6672G>C)
with clozapine-induced neutropenia and agranulocytosis
in individuals of European ancestry. We showed that local
haplotype structure might be an important factor when
considering regions containing an excess of ancestry
switches, as is the case for the MHC region, and that these
patterns might be relevant for determining risk. These
findings could lead to novel insights into the pathogenesis
of neutropenia and agranulocytosis. Using local ancestry
estimates for prediction increased the sensitivity of
rs113332494. Further studies are required to clarify the
role of the marker rs113332494 and to analyse the influ-
ence of global and local ancestry patterns.
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